Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
FDA Approves Powerful Synthetic Opioid
The U.S. Food and Drug Administration (FDA) has approved a new form of the synthetic opioid sufentanil for the management of acute pain in...
CMS Finalizes Physician Fee Schedule for 2019
The Centers for Medicare and Medicaid Services (CMS) has finalized changes to the Medicare Physician Fee Schedule and the Quality Payment Program for 2019,...
Gene Therapy Suppliers Foresee Struggle to Meet Demand
Despite high costs, gene therapy manufacturing has thus far been able to keep pace with demand, but that could change, as treatments for hemophilia...
Administration Unveils Changes to Medicare Drug Payments
In a speech at the U.S. Department of Health and Human Services (HHS) last month, President Donald Trump outlined a proposal for a pilot...
President Signs Bipartisan Opioid Bill
President Donald Trump has signed a spending package addressing the nationwide opioid addiction crisis that contributed to more than 70,000 overdose deaths in 2017....
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
